Evaluation of the Trivedi Effect®- Energy of Consciousness Energy Healing Treatment on the Physical, Spectral, and Thermal Properties of Zinc Chloride

Zinc chloride has the importance in pharmaceutical/nutraceutical industries for the prevention and treatment of several diseases. The objective of the current study was to investigate the impact of The Trivedi Effect®-Energy of Consciousness Healing Treatment (Biofield Energy Healing Treatment) on physical, structural, and thermal properties of zinc chloride using PXRD, PSD, FT-IR, UV-vis, TGA, and DSC analysis. Zinc chloride was divided into two parts. One part was denoted as the control without any, while the other part was defined as the Trivedi Effect® Treated sample, which received the Trivedi Effect® Treatment remotely from eighteen renowned Biofield Energy Healers. The PXRD analysis revealed that the crystallite size and relative intensities of the PXRD peaks significantly altered in the treated sample compared with the control sample. The crystallite size of treated sample was decreased by 4.19% compared with the control sample. The particle size at d10 and d50 of the Biofield Energy Treated sample decreased by 4.72% and 2.70%, respectively compared with the control sample. But, the particle size of the treated sample increased at d90 by 0.83 compared with the control sample. Consequently, the surface area was increased by 3.22% in the treated sample compared with the control sample. The FT-IR spectroscopic analysis revealed that Zn-Cl stretching in the control and treated sample was at 520 cm-1 and 521 cm-1, respectively. The UV-vis analysis exhibited that the wavelength of the maximum absorbance of the control and treated samples was at 196.4 and 196.2 nm, respectively. The TGA thermograms revealed two steps of the thermal degradation and the weight loss of the treated sample was significantly reduced by 22.54% in the 1st step of degradation compared with the control sample. The DSC analysis showed that the enthalpy of decomposition was significantly increased by 34.9% in the treated sample (89.17 J/g) compared with the control sample (66.10 J/g). Overall, DSC and TGA analysis indicated that the thermal stability of the treated sample was increased compared with the control sample. The current study anticipated that The Trivedi Effect®-Energy of Consciousness Healing Treatment might lead to generate a new polymorphic form of zinc chloride, which would be more soluble, stable, and higher absorption rate compared with the control sample. Hence, the treated zinc chloride could be very useful to design the various forms of nutraceuticals and pharmaceutical formulation which might be providing a better therapeutic response against inflammatory diseases, immunological disorders, aging, stress, cancer, etc. https://www.trivedieffect.com/science/evaluation-of-the-trivedi-effect-energy-of-consciousness-energy-healing-treatment-on-the-physical-spectral-and-thermal-properties-of-zinc-chloride http://www.sciencepublishinggroup.com/journal/paperinfo?journalid=118&doi=10.11648/j.ajls.20170501.1

ESA Voyage 2050 White Paper: Detecting life outside our solar system with a large high-contrast-imaging mission

In this white paper, we recommend the European Space Agency plays a proactive role in developing a global collaborative effort to construct a large high-contrast imaging space telescope, e.g. as currently under study by NASA. Such a mission will be needed to characterize a sizable sample of temperate Earth-like planets in the habitable zones of nearby Sun-like stars and to search for extraterrestrial biological activity. We provide an overview of relevant European expertise, and advocate ESA to start a technology development program towards detecting life outside the Solar system

ESA Voyage 2050 White Paper: Detecting life outside our solar system with a large high-contrast-imaging mission

White paper for ESA Voyage 2050In this white paper, we recommend the European Space Agency plays a proactive role in developing a global collaborative effort to construct a large high-contrast imaging space telescope, e.g. as currently under study by NASA. Such a mission will be needed to characterize a sizable sample of temperate Earth-like planets in the habitable zones of nearby Sun-like stars and to search for extraterrestrial biological activity. We provide an overview of relevant European expertise, and advocate ESA to start a technology development program towards detecting life outside the Solar system

ESA Voyage 2050 White Paper: Detecting life outside our solar system with a large high-contrast-imaging mission

White paper for ESA Voyage 2050In this white paper, we recommend the European Space Agency plays a proactive role in developing a global collaborative effort to construct a large high-contrast imaging space telescope, e.g. as currently under study by NASA. Such a mission will be needed to characterize a sizable sample of temperate Earth-like planets in the habitable zones of nearby Sun-like stars and to search for extraterrestrial biological activity. We provide an overview of relevant European expertise, and advocate ESA to start a technology development program towards detecting life outside the Solar system

Atmospheric characterization of terrestrial exoplanets in the mid-infrared: biosignatures, habitability & diversity

Submitted to ESA in response to the Call for White Papers for the Voyage 2050 long-term plan in the ESA Science ProgrammeExoplanet science is one of the most thriving fields of modern astrophysics. A major goal is the atmospheric characterization of dozens of small, terrestrial exoplanets in order to search for signatures in their atmospheres that indicate biological activity, assess their ability to provide conditions for life as we know it, and investigate their expected atmospheric diversity. None of the currently adopted projects or missions, from ground or in space, can address these goals. In this White Paper we argue that a large space-based mission designed to detect and investigate thermal emission spectra of terrestrial exoplanets in the MIR wavelength range provides unique scientific potential to address these goals and surpasses the capabilities of other approaches. While NASA might be focusing on large missions that aim to detect terrestrial planets in reflected light, ESA has the opportunity to take leadership and spearhead the development of a large MIR exoplanet mission within the scope of the "Voyage 2050" long-term plan establishing Europe at the forefront of exoplanet science for decades to come. Given the ambitious science goals of such a mission, additional international partners might be interested in participating and contributing to a roadmap that, in the long run, leads to a successful implementation. A new, dedicated development program funded by ESA to help reduce development and implementation cost and further push some of the required key technologies would be a first important step in this direction. Ultimately, a large MIR exoplanet imaging mission will be needed to help answer one of mankind's most fundamental questions: "How unique is our Earth?

The PRSS3P2 and TRY7 deletion copy number variant modifies risk for chronic pancreatitis

Background PRSS1 and PRSS2 constitute the only functional copies of a tandemly-arranged five-trypsinogen-gene cluster (i.e., PRSS1, PRSS3P1, PRSS3P2, TRY7 and PRSS2) on chromosome 7q35. Variants in PRSS1 and PRSS2, including missense and copy number variants (CNVs), have been reported to predispose to or protect against chronic pancreatitis (CP). We wondered whether a common trypsinogen pseudogene deletion CNV (that removes two of the three trypsinogen pseudogenes, PRSS3P2 and TRY7) might be associated with CP causation/predisposition. Methods We analyzed the common PRSS3P2 and TRY7 deletion CNV in a total of 1536 CP patients and 3506 controls from France, Germany, India and Japan by means of quantitative fluorescent multiplex polymerase chain reaction. Results We demonstrated that the deletion CNV variant was associated with a protective effect against CP in the French, German and Japanese cohorts whilst a trend toward the same association was noted in the Indian cohort. Meta-analysis under a dominant model yielded a pooled odds ratio (OR) of 0.68 (95% confidence interval (CI) 0.52–0.89; p = 0.005) whereas an allele-based meta-analysis yielded a pooled OR of 0.84 (95% CI 0.77–0.92; p = 0.0001). This protective effect is explicable by reference to the recent finding that the still functional PRSS3P2/TRY7 pseudogene enhancers upregulate pancreatic PRSS2 expression. Conclusions The common PRSS3P2 and TRY7 deletion CNV was associated with a reduced risk for CP. This finding provides additional support for the emerging view that dysregulated PRSS2 expression represents a discrete mechanism underlying CP predisposition or protection

Pancreatology

BACKGROUND: PRSS1 and PRSS2 constitute the only functional copies of a tandemly-arranged five-trypsinogen-gene cluster (i.e., PRSS1, PRSS3P1, PRSS3P2, TRY7 and PRSS2) on chromosome 7q35. Variants in PRSS1 and PRSS2, including missense and copy number variants (CNVs), have been reported to predispose to or protect against chronic pancreatitis (CP). We wondered whether a common trypsinogen pseudogene deletion CNV (that removes two of the three trypsinogen pseudogenes, PRSS3P2 and TRY7) might be associated with CP causation/predisposition. METHODS: We analyzed the common PRSS3P2 and TRY7 deletion CNV in a total of 1536 CP patients and 3506 controls from France, Germany, India and Japan by means of quantitative fluorescent multiplex polymerase chain reaction. RESULTS: We demonstrated that the deletion CNV variant was associated with a protective effect against CP in the French, German and Japanese cohorts whilst a trend toward the same association was noted in the Indian cohort. Meta-analysis under a dominant model yielded a pooled odds ratio (OR) of 0.68 (95% confidence interval (CI) 0.52-0.89; p = 0.005) whereas an allele-based meta-analysis yielded a pooled OR of 0.84 (95% CI 0.77-0.92; p = 0.0001). This protective effect is explicable by reference to the recent finding that the still functional PRSS3P2/TRY7 pseudogene enhancers upregulate pancreatic PRSS2 expression. CONCLUSIONS: The common PRSS3P2 and TRY7 deletion CNV was associated with a reduced risk for CP. This finding provides additional support for the emerging view that dysregulated PRSS2 expression represents a discrete mechanism underlying CP predisposition or protection

The PRSS3P2 and TRY7 deletion copy number variant modifies risk for chronic pancreatitis

International audienc